STEPHEN DAVIS Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for STEPHEN DAVIS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of STEPHEN DAVIS. STEPHEN DAVIS is Director in HERON THERAPEUTICS, INC. /DE/ ($HRTX) and Exec. VP, Chief Oper. Officer in NEUROGEN CORP ($NRGN) and President in NEUROGEN CORP ($NRGN) and President, CEO in NEUROGEN CORP ($NRGN) and Sr VP, Chief Business Officer in NEUROGEN CORP ($NRGN) and Sr VP, Chief Operating Officer in NEUROGEN CORP ($NRGN) and Director in SYNAGEVA BIOPHARMA CORP ($GEVA) and CEO in ACADIA PHARMACEUTICALS INC ($ACAD) and INTERIM CEO in ACADIA PHARMACEUTICALS INC ($ACAD) and PRESIDENT AND CEO in ACADIA PHARMACEUTICALS INC ($ACAD) and Director in BELLICUM PHARMACEUTICALS, INC ($BLCM).
Latest Insider Trading Transactions of STEPHEN DAVIS
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACAD, BLCM, HRTX, NRGN, GEVA
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 2021 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | M | 0.00 | 15,625 | 0 | 31,250 | |
| Apr 30 2021 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 20.33 | 7,850 | 159,591 | 49,312 | 57.2 K to 49.3 K (-13.73 %) |
| Apr 30 2021 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Buy | M | 0.00 | 15,625 | 0 | 57,162 | 41.5 K to 57.2 K (+37.62 %) |
| Feb 25 2021 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | A | 0.00 | 43,782 | 0 | 43,782 | |
| Feb 25 2021 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | A | 49.74 | 161,230 | 8,019,580 | 161,230 | |
| Feb 08 2021 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | A | 21.28 | 23,750 | 505,400 | 23,750 | |
| Feb 08 2021 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | A | 35.80 | 40,625 | 1,454,375 | 40,625 | |
| Feb 08 2021 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | A | 29.59 | 40,625 | 1,202,094 | 40,625 | |
| Feb 08 2021 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 50.61 | 14,195 | 718,409 | 28,900 | 43.1 K to 28.9 K (-32.94 %) |
| Feb 08 2021 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Grant | A | 0.00 | 31,250 | 0 | 43,059 | 11.8 K to 43.1 K (+264.63 %) |
| Jan 08 2021 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | M | 0.00 | 9,527 | 0 | 28,583 | |
| Jan 08 2021 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 53.34 | 3,484 | 185,837 | 24,482 | 28 K to 24.5 K (-12.46 %) |
| Jan 08 2021 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Buy | M | 0.00 | 9,527 | 0 | 27,966 | 18.4 K to 28 K (+51.67 %) |
| Dec 23 2020 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Option Exercise | A | 19.46 | 18,000 | 350,280 | 18,000 | |
| Dec 23 2020 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Grant | A | 0.00 | 3,000 | 0 | 3,000 | 0 to 3 K |
| Oct 19 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | M | 0.00 | 5,937 | 0 | 11,876 | |
| Oct 19 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 42.56 | 2,960 | 125,978 | 14,786 | 17.7 K to 14.8 K (-16.68 %) |
| Oct 19 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Buy | M | 0.00 | 5,937 | 0 | 17,746 | 11.8 K to 17.7 K (+50.28 %) |
| Oct 15 2020 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Option Exercise | A | 15.72 | 765 | 12,026 | 765 | |
| Jun 16 2020 | BLCM | BELLICUM PHARMACEU ... | DAVIS STEPHEN | Director | Option Exercise | A | 8.42 | 6,500 | 54,730 | 6,500 | |
| Jun 16 2020 | BLCM | BELLICUM PHARMACEU ... | DAVIS STEPHEN | Director | Option Exercise | A | 8.42 | 6,500 | 54,730 | 6,500 | |
| May 15 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | M | 19.65 | 88,542 | 1,739,850 | 100,000 | |
| May 15 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | M | 19.65 | 111,458 | 2,190,150 | 188,542 | |
| May 15 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 45.01 | 4,321 | 194,509 | 11,809 | 16.1 K to 11.8 K (-26.79 %) |
| May 15 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 45.65 | 84,221 | 3,844,596 | 16,130 | 100.4 K to 16.1 K (-83.93 %) |
| May 15 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Buy | M | 19.65 | 88,542 | 1,739,850 | 100,351 | 11.8 K to 100.4 K (+749.78 %) |
| May 15 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 45.12 | 8,197 | 369,827 | 11,809 | 20 K to 11.8 K (-40.97 %) |
| May 15 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 45.71 | 63,392 | 2,897,858 | 20,006 | 83.4 K to 20 K (-76.01 %) |
| May 15 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 46.43 | 20,756 | 963,705 | 83,398 | 104.2 K to 83.4 K (-19.93 %) |
| May 15 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 48.60 | 5,205 | 252,953 | 104,154 | 109.4 K to 104.2 K (-4.76 %) |
| May 15 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 48.98 | 13,908 | 681,244 | 109,359 | 123.3 K to 109.4 K (-11.28 %) |
| May 15 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Buy | M | 19.65 | 111,458 | 2,190,150 | 123,267 | 11.8 K to 123.3 K (+943.84 %) |
| May 01 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | M | 0.00 | 15,625 | 0 | 46,875 | |
| May 01 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 49.21 | 6,770 | 333,152 | 11,809 | 18.6 K to 11.8 K (-36.44 %) |
| May 01 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Buy | M | 0.00 | 15,625 | 0 | 18,579 | 3 K to 18.6 K (+528.94 %) |
| Apr 17 2020 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Option Exercise | A | 14.44 | 1,426 | 20,591 | 1,426 | |
| Jan 08 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | A | 0.00 | 38,110 | 0 | 38,110 | |
| Jan 08 2020 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | A | 42.81 | 138,304 | 5,920,794 | 138,304 | |
| Dec 23 2019 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Option Exercise | A | 25.02 | 15,500 | 387,810 | 15,500 | |
| Dec 06 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | M | 19.65 | 150,000 | 2,947,500 | 300,000 | |
| Dec 06 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 51.32 | 28,256 | 1,450,098 | 2,954 | 31.2 K to 3 K (-90.54 %) |
| Dec 06 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 52.09 | 40,159 | 2,091,882 | 31,210 | 71.4 K to 31.2 K (-56.27 %) |
| Dec 06 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 52.82 | 81,585 | 4,309,320 | 71,369 | 153 K to 71.4 K (-53.34 %) |
| Dec 06 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Buy | M | 19.65 | 150,000 | 2,947,500 | 152,954 | 3 K to 153 K (+5,077.86 %) |
| Oct 17 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | M | 0.00 | 5,937 | 0 | 17,813 | |
| Oct 17 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 39.65 | 2,983 | 118,276 | 2,954 | 5.9 K to 3 K (-50.24 %) |
| Oct 17 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Buy | M | 0.00 | 5,937 | 0 | 5,937 | 0 to 5.9 K |
| Oct 11 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | M | 19.65 | 120,208 | 2,362,087 | 450,000 | |
| Oct 11 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Option Exercise | M | 19.65 | 29,792 | 585,413 | 570,208 | |
| Oct 11 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 40.19 | 120,208 | 4,831,039 | 0 | 120.2 K to 0 (-100.00 %) |
| Oct 11 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Buy | M | 19.65 | 120,208 | 2,362,087 | 120,208 | 0 to 120.2 K |
| Oct 11 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Sell | S | 40.00 | 29,792 | 1,191,710 | 0 | 29.8 K to 0 (-100.00 %) |
| Oct 11 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | CEO | Buy | M | 19.65 | 29,792 | 585,413 | 29,792 | 0 to 29.8 K |
| Oct 01 2019 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Option Exercise | A | 17.56 | 750 | 13,170 | 750 | |
| Oct 01 2019 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Option Exercise | A | 17.56 | 25,000 | 439,000 | 25,000 | |
| Jun 14 2019 | BLCM | BELLICUM PHARMACEU ... | DAVIS STEPHEN | Director | Option Exercise | A | 1.96 | 25,000 | 49,000 | 25,000 | |
| May 01 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | President and CEO | Option Exercise | A | 0.00 | 62,500 | 0 | 62,500 | |
| May 01 2019 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | President and CEO | Option Exercise | A | 25.12 | 219,298 | 5,508,766 | 219,298 | |
| Oct 24 2018 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | PRESIDENT AND CEO | Option Exercise | A | 0.00 | 23,750 | 0 | 23,750 | |
| Oct 24 2018 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | PRESIDENT AND CEO | Option Exercise | A | 21.28 | 95,000 | 2,021,600 | 95,000 | |
| Jun 18 2018 | BLCM | BELLICUM PHARMACEU ... | DAVIS STEPHEN | Director | Option Exercise | A | 9.80 | 10,000 | 98,000 | 10,000 | |
| Apr 20 2018 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | PRESIDENT AND CEO | Option Exercise | A | 19.98 | 135,000 | 2,697,300 | 135,000 | |
| Sep 08 2017 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | PRESIDENT AND CEO | Option Exercise | A | 35.80 | 243,750 | 8,726,250 | 243,750 | |
| Jun 15 2017 | BLCM | BELLICUM PHARMACEU ... | DAVIS STEPHEN | Director | Option Exercise | A | 10.34 | 10,000 | 103,400 | 10,000 | |
| Jun 15 2017 | BLCM | BELLICUM PHARMACEU ... | DAVIS STEPHEN | Director | Option Exercise | A | 10.34 | 10,000 | 103,400 | 10,000 | |
| Mar 10 2017 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | PRESIDENT AND CEO | Option Exercise | A | 36.54 | 243,750 | 8,906,625 | 243,750 | |
| Jun 17 2016 | BLCM | BELLICUM PHARMACEU ... | DAVIS STEPHEN | Director | Option Exercise | A | 12.44 | 10,000 | 124,400 | 10,000 | |
| Mar 17 2016 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | PRESIDENT AND CEO | Option Exercise | A | 19.65 | 600,000 | 11,790,000 | 600,000 | |
| Sep 03 2015 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | PRESIDENT AND CEO | Option Exercise | A | 35.91 | 225,000 | 8,079,750 | 225,000 | |
| Jul 15 2015 | BLCM | BELLICUM PHARMACEU ... | DAVIS STEPHEN | Director | Option Exercise | A | 20.25 | 9,167 | 185,632 | 9,167 | |
| Jul 15 2015 | BLCM | BELLICUM PHARMACEU ... | DAVIS STEPHEN | Director | Option Exercise | A | 20.25 | 20,000 | 405,000 | 20,000 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | DAVIS STEPHEN | Director | Option Exercise | D | 80.35 | 7,500 | 602,625 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | DAVIS STEPHEN | Director | Option Exercise | D | 40.74 | 7,500 | 305,550 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | DAVIS STEPHEN | Director | Option Exercise | D | 40.32 | 7,500 | 302,400 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | DAVIS STEPHEN | Director | Option Exercise | D | 25.00 | 3,000 | 75,000 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | DAVIS STEPHEN | Director | Option Exercise | D | 23.95 | 4,000 | 95,800 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | DAVIS STEPHEN | Director | Option Exercise | D | 23.00 | 15,000 | 345,000 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | DAVIS STEPHEN | Director | Option Exercise | D | 20.60 | 3,000 | 61,800 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | DAVIS STEPHEN | Director | Option Exercise | D | 11.35 | 3,000 | 34,050 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | DAVIS STEPHEN | Director | Option Exercise | D | 10.10 | 3,000 | 30,300 | 0 | |
| Mar 24 2015 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | INTERIM CEO | Option Exercise | A | 34.45 | 120,000 | 4,134,000 | 120,000 | |
| Mar 24 2015 | ACAD | ACADIA PHARMACEUTI ... | DAVIS STEPHEN | INTERIM CEO | Option Exercise | A | 34.45 | 100,000 | 3,445,000 | 100,000 | |
| Jul 29 2008 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | President, CEO | Option Exercise | A | 1.20 | 224,000 | 268,800 | 224,000 | |
| Apr 28 2008 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | Exec. VP, Chief Ope ... | Option Exercise | A | 1.20 | 476,000 | 571,200 | 476,000 | |
| Dec 21 2007 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | President | Option Exercise | A | 3.56 | 26,250 | 93,450 | 26,250 | |
| Jan 19 2007 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | Exec. VP, Chief Ope ... | Option Exercise | A | 6.20 | 120,000 | 744,000 | 120,000 | |
| Dec 19 2006 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | Exec. VP, Chief Ope ... | Option Exercise | A | 5.78 | 36,400 | 210,392 | 36,400 | |
| Dec 20 2005 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | Sr VP, Chief Operat ... | Option Exercise | A | 7.88 | 27,720 | 218,434 | 27,720 | |
| Dec 23 2004 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | Sr VP, Chief Busine ... | Option Exercise | M | 3.87 | 12 | 46 | 0 | |
| Dec 23 2004 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | Sr VP, Chief Busine ... | Option Exercise | M | 3.87 | 17,488 | 67,679 | 0 | |
| Dec 23 2004 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | Sr VP, Chief Busine ... | Option Exercise | A | 9.05 | 100,000 | 905,000 | 100,000 | |
| Dec 23 2004 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | Sr VP, Chief Busine ... | Grant | A | 9.15 | 487 | 4,456 | 5,979 | 5.5 K to 6 K (+8.87 %) |
| Dec 23 2004 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | Sr VP, Chief Busine ... | Sell | S | 9.55 | 12 | 115 | 50,750 | 50.8 K to 50.8 K (-0.02 %) |
| Dec 23 2004 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | Sr VP, Chief Busine ... | Buy | M | 3.87 | 12 | 46 | 0 | -12 to 0 (-100.00 %) |
| Dec 23 2004 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | Sr VP, Chief Busine ... | Sell | S | 9.00 | 17,488 | 157,392 | 0 | 17.5 K to 0 (-100.00 %) |
| Dec 23 2004 | NRGN | NEUROGEN CORP | DAVIS STEPHEN | Sr VP, Chief Busine ... | Buy | M | 3.87 | 17,488 | 67,679 | 0 | -17,488 to 0 (-100.00 %) |
Page: 1